Will Shareholders Support The Bristol/Celgene Merger? – An Informa Pharma Intelligence Podcast

Expectations that the $74bn deal will go through are now reinforced by proxy advisor recommendations that shareholders vote in favor of the transaction. Podcast discussion also includes Karyopharm’s selinexor and J&J’s Spravato.

Man hand with pen over document, select Yes or No.

Bristol-Myers Squibb Co.'s plan to buy Celgene Corp. for $74bn made investors optimistic about biopharmaceutical stocks again, but opposition from some of Bristol's major shareholders put the deal in doubt – though it now seems more likely that the transaction will go through.

That's because the independent proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis & Co

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

14 May 2025

• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

14 May 2025

• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

14 May 2025

• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

14 May 2025

• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.